



Sociedad Española  
de Reumatología -  
Colegio Mexicano  
de Reumatología

# Reumatología Clínica

www.reumatologiaclinica.org



## Original Article

### Development and feasibility of 4 checklists for the evaluation of comorbidity in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis: GECOAI Project<sup>☆</sup>



Santos Castañeda,<sup>a,\*</sup> Carlos González,<sup>b</sup> Virginia Villaverde,<sup>c</sup> Cristina Lajas Petisco,<sup>d</sup> María Carmen Castro,<sup>e</sup> Fernando Jirout,<sup>f</sup> Juan Carlos Obaya,<sup>g</sup> Juan Carlos Hermosa,<sup>h</sup> Carmen Suárez,<sup>i</sup> Silvia García,<sup>j</sup> María Rodero,<sup>d</sup> Leticia León,<sup>d</sup> Amparo López Esteban,<sup>b</sup> Milena Gobbo,<sup>k</sup> Laly Alcaide,<sup>l</sup> Juan Carlos Torre-Alonso<sup>f</sup>

<sup>a</sup> Servicio de Reumatología, Hospital Universitario de la Princesa, IIS-Princesa, Cátedra UAM-ROCHE, EPID-Futuro, Universidad Autónoma de Madrid (UAM), Madrid, Spain

<sup>b</sup> Servicio de Reumatología, Hospital Universitario Gregorio Marañón, Madrid, Spain

<sup>c</sup> Servicio de Reumatología, Hospital Universitario de Móstoles, Madrid, Spain

<sup>d</sup> Servicio de Reumatología, IDISSC, Hospital Universitario Clínico de San Carlos, Madrid, Spain

<sup>e</sup> Servicio de Reumatología, Hospital Universitario Reina Sofía, Córdoba, Spain

<sup>f</sup> Servicio de Reumatología, Hospital Monte Naranco, Oviedo, Spain

<sup>g</sup> Centro de Salud Alcobendas, Madrid, Spain

<sup>h</sup> Centro de Salud Ciudades, Getafe, Madrid, Spain

<sup>i</sup> Servicio de Medicina Interna, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain

<sup>j</sup> Servicio de Reumatología, Hospital Moises Broggi, Sant Joan Despí, Barcelona, Spain

<sup>k</sup> Positivamente Centro de Psicología, Madrid, Spain

<sup>l</sup> Coordinadora Nacional de Artritis, Madrid, Spain

## ARTICLE INFO

### Article history:

Received 25 November 2019

Accepted 3 September 2020

Available online 7 April 2021

### Keywords:

Rheumatoid arthritis  
Axial spondyloarthritis  
Psoriatic arthritis  
Comorbidity  
Checklist  
Feasibility

## ABSTRACT

**Objective:** To develop and assess the feasibility in daily practice of four comorbidity checklists, for common use in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).

**Methods:** A multidisciplinary panel of experts on comorbidity was established. Data from the GECOAR, GECOAX and GECOAP projects were analysed and a narrative literature review in Medline on RA, axSpA and PsA comorbidity was performed in order to select the most relevant and common comorbidities across the three diseases. With these results and those obtained from a focus group of patients, in a nominal group meeting, the experts generated preliminary checklists. These were afterwards modified by an external evaluation by two associations, a patients' association and an association of health professionals related to rheumatology. As a result, the final checklists were generated. A cross-sectional study was conducted to test the feasibility of three of the checklists in daily practice, in which eight health professionals evaluated the checklists in five patients with RA, five with axSpA and five with SpA.

**Results:** Four comorbidity checklists were designed, three for health professionals (one to assess current comorbidity, one on prevention/health promotion and one with the referral criteria to other health professionals), and another for patients. The feasibility study showed them to be simple, clear, and useful for use in routine clinical practice.

**Conclusions:** The use of specific and common checklists for patients with RA, axSpA and PsA is feasible and might contribute favorably to their prognosis as well as in daily practice.

© 2020 The Authors. Published by Elsevier España, S.L.U. All rights reserved.

<sup>☆</sup> Please cite this article as: Castañeda S, González C, Villaverde V, Lajas Petisco C, Castro MC, Jirout F, et al. Desarrollo y viabilidad de cuatro *checklists* para la evaluación de la comorbilidad en pacientes con artritis reumatoide, espondiloartritis axial y artritis psoriásica: Proyecto GECOAI. Reumatol Clin. 2022;18:114–123.

\* Corresponding author.

E-mail address: scastas@gmail.com (S. Castañeda).

**Palabras clave:**

Artritis reumatoide  
 Espondiloartritis axial  
 Artritis psoriásica  
 Comorbilidad  
 Checklist  
 Viabilidad

## Desarrollo y viabilidad de cuatro *checklists* para la evaluación de la comorbilidad en pacientes con artritis reumatoide, espondiloartritis axial y artritis psoriásica: Proyecto GECOAI

### R E S U M E N

**Objetivo:** Desarrollar y analizar la viabilidad en la práctica diaria de cuatro *checklists* relacionados con la comorbilidad, comunes para pacientes con artritis reumatoide (AR), espondiloartritis axial (EspAax) y artritis psoriásica (APs).

**Métodos:** Se estableció un grupo multidisciplinar de expertos en comorbilidad. Se revisaron los proyectos GECOAR, GECOAX y GECOAP, y se realizó una búsqueda bibliográfica en Medline sobre comorbilidad en AR, EspAax y APs, para seleccionar las comorbilidades más relevantes y comunes a las tres enfermedades. Con estos resultados y los obtenidos de un grupo focal de pacientes, en una reunión de grupo nominal, los expertos generaron unos *checklists* preliminares. Estos listados preliminares se modificaron, tras una evaluación externa por una asociación de pacientes y otra de profesionales de la salud relacionados con la reumatología, para generar los *checklists* definitivos. Finalmente, se realizó un estudio transversal, en el que ocho profesionales de la salud evaluaron tres *checklists* en cinco pacientes con AR, cinco con EspAax y cinco con APs.

**Resultados:** Se diseñaron cuatro *checklists* de comorbilidad, tres para profesionales de la salud (uno sobre evaluación de la comorbilidad presente, otro sobre prevención/promoción de la salud y un último con los criterios de derivación a otros profesionales), y otro para pacientes. El estudio de viabilidad mostró que son sencillos, claros y útiles para su uso en la práctica clínica habitual.

**Conclusiones:** El uso de *checklists* específicos y comunes para pacientes con AR, EspAax y APs es factible y puede contribuir favorablemente en su pronóstico así como en la práctica clínica habitual.

© 2020 Los Autores. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Introduction

Rheumatoid arthritis (AR), axial spondyloarthritis (AxSpA) and psoriatic arthritis (PsA) are common chronic inflammatory diseases in the general population.<sup>1–3</sup>

Furthermore, this group of diseases has been shown to have a high prevalence of comorbidities,<sup>4</sup> many of them common to the three entities, where comorbidity and cardiovascular (CV) risk factors are notable. Thus, for example, the COMORA study, which was a transversal study conducted in 17 countries with almost 4000 patients with RA, demonstrated high blood pressure (HBP) prevalence of 40.4%, hypercholesterolaemia of 31.7% and 15% depression in these patients.<sup>5</sup> The COMOSPA study, which was similar to the previous one, was conducted in 22 countries and assessed over 3000 consecutive patients with axial spondyloarthritis and reported the prevalence of different comorbidities.<sup>6</sup> A prevalence of 33.5% HBP was estimated, together with 29.3% for a tobacco habit, 27.3% for hypercholesterolaemia, 13% osteoporosis, 11% gastroduodenal ulcer and 4% for CV events. Similar findings were reported in the Spanish population.<sup>7</sup> Finally, in patients with PsA prevalence of HBP, Diabetes Mellitus (DM), obesity and metabolic syndrome have been reported up to 37%, 12%, 30% and 40%, respectively.<sup>8,9</sup>

Also, different publications have shown the great impact comorbidity has had on these patients.<sup>10,11</sup> In one prospective cohort of patients with RA it was demonstrated that the higher the number of comorbidities, the poorer the functional status, regardless of disease activity.<sup>12</sup> The CARMA study also reported in patients with ankylosing spondylitis and PsA an independent association between comorbidity and a poorer functional status.<sup>13</sup>

Due to all of the above, different projects have been developed to address the management of comorbidity in these illnesses. These include the GECOAR Project in RA,<sup>14</sup> GECOAX in AxSpA<sup>15</sup> and GECOAP in PsA,<sup>16</sup> and aim to promote a framework in management. They all contain explicit recommendations and even other materials for the identification, assessment and control of the comorbidity. The fact that there are specific approaches may be highly beneficial in clinical practice since they are very much aimed at each type of patient. However, on the other hand, the lack of time, and especially in those centres with a high healthcare load, this may be a limiting factor when following the recommendations of these documents.

Based on the above, and bearing in mind that the three diseases share many comorbidities, the aim of the GECOAI Project (inflammatory arthritis comorbidity management) was to create common support documents for the three diseases for all health professionals involved in the management of these conditions, and also for the patients. The purpose was to more effectively manage possible associated comorbidities and therefore reduce the variability in the management of patients with RA, AxSpA and PsA.

## Methods

### Study design

This was a mixed design study (qualitative and quantitative). For the development of the checklists qualitative study methodology was followed based on narrative review of the literature, a focus group of patients and a nominal group of experts. For the feasibility study a cross-sectional observation study was conducted. The project was carried out in keeping with the good clinical practices regulations/guidelines and the current version of the revised declaration of Helsinki. It also had the endorsement of the Rheumatology Society of the Community of Madrid (SORCOM), OPENREUMA and the National Arthritis Coordinators (ConArtritis).

### Participant selection

In the first place a multidisciplinary group of healthcare professionals was established with interest and experience in the management of patients with RA, AxSpA and PsA, formed by seven rheumatologists (three of them were the project coordinators), two primary care physicians, an internal medicine expert in CV comorbidity, three nurses and one psychologist.

### Development of checklists

During the first phase three main documents were reviewed<sup>14–16</sup> and a narrative review of the literature was made in search of articles on the management of comorbidity in RA, AxSpA and PsA. Recordings were made of the comorbidities

to assess in normal practice, their form of assessment and their rates. The Pubmed *Clinical Queries* were used, and small strategies of search using Mesh and free text terms. All this information was presented and discussed with the three project coordinators who selected the comorbidities and elements considered relevant (in relation to prevalence and impact of comorbidity or capacity for its prevention) and cross-sectional (common to the three diseases). These included pharmacological allergies, current medication and possible related problems (tolerance, adherence, etc.), together with CV comorbidities and CV risk factors, infections and vaccines, depression, osteoporosis, gastrointestinal comorbidities and others, such as uveitis. After this, the previously exposed results were presented in a focus group of patients with RA, PsA and AxSpA, for which a typological box was designed to include heterogeneous and representative people. The focus group lasted 95 min and an audio recorder was used to record the detailed discussion. The following aspects, among others, were discussed: medical and patient terminology related to comorbidities; their opinion on which comorbidities would be important to know about, and comprehensible ways of identifying and reporting them.

Everything that was collected in the previous steps was later addressed in a nominal group meeting in which the multidisciplinary health professionals took part, with the exception of the three coordinators. After reviewing all data consensus was reached to create three types of checklists, a specific one for patients, aimed at facilitating posterior assessment by health professionals, and another three specific ones for the healthcare professionals. One was for assessment of current comorbidity, another focused on comorbidity prevention and health promotion and the last on assessment for possible referral to another healthcare professional. The variables to be included in each checklist and their type of evaluation were also agreed. These were then produced and set up in a preliminary fashion for use in daily practice.

The specific comorbidity checklist for patients was analysed by ConArtritis (its objectives, content and clarity) and all the checklists by OPENREUMA. Both associations evaluated the aims, their content and their clarity. The comments of the two associations were reviewed and considered by the coordinators who defined the final checklists which were formatted in their final version.

### Feasibility study

Feasibility in clinical practice of the three checklists relating to healthcare professionals was confirmed by a small cross-sectional study. Eight members of the multi disciplinary group (five rheumatologists and three nurses) took part. Each of them applied the three checklists to 15 patients (five with RA, five with AxSpA, and five with PsA) from their regular practice. After this, they filled in a specific data collection book which included: 1) Centre characteristics; service (including members and presence of monographic consultations of RA, AxSpA and PsA); characteristics of the professional; 2) checklist characteristics relating to time of completion (in minutes); simplicity, user-friendliness and general usefulness, recorded on a scale of 0 (not at all) to 10 (very, a lot); impact in daily practice improvement (assessing of comorbidity, prevention of the same and referral to other healthcare professionals) and its need for review were responded to with yes/no; 3) Other factors, such as its recommendation to other colleagues (yes/no) and further comments.

### Statistical analysis

For the feasibility study a descriptive study was made on the data. The quantitative variables were described using mean and

standard deviation and the qualitative with frequencies and percentages.

## Results

### Checklists

Four checklists were created relating to comorbidity, one specifically for patients (Fig. 1) and three for health professionals responsible for the care of patients with RA, AxSpA and PsA. One related to the assessment of comorbidity (Fig. 2), another to the prevention of it and health promotion (Fig. 3) and another for referral to other healthcare professionals (Fig. 4).

The checklist for patients (Fig. 1), begins with an explanation of the objectives pursued and contains 13 comprehensively formulated questions approved by the patients themselves. Relevant comorbidities are included about which both professionals and patients agreed were comprehensible and simple to reliably report on. They address the disease suffered from and the medication related to it, toxic habits (tobacco and alcohol) and, through the use of direct, and indirect questions, or scales, they assess the mood, infections, vaccines, ocular pathology and bone metabolism. They also allude to visits to emergency services since these could indicate a serious episode related to the comorbidity under study, or of some other type.

The assessment checklist of comorbidity for healthcare professionals (Fig. 2) includes, initially, three spaces for free text on pharmacological allergies, current medication and free comments (if they are considered necessary). This is followed by a section on cardiovascular pathology and CV risks factors. In this part previous events may be recorded and variables such as weight, toxic habits, concentrations of cholesterol or regular exercise. They also evaluate a history of neoplasia (type, date and status), the presence of depression, infections (including their severity, vaccines and serologies) and other complications related with AR, AxSpA and PsA. A series of general indications are provided at the end and indication on the main comorbidity assessment rate.

The comorbidity prevention and health promotion checklist (Fig. 3) includes preventable comorbidities (and how to assess/measure them), for the purpose of confirming that all the right procedures have been taken relating to the prevention of the comorbidity and the promotion of health in patients with this group of diseases. Among other factors are diet, the risk of fracture, oral hygiene, adherence to treatment and sleep and social life assessment. With regards to the format of assessment, direct questions are included as is the use of specific questionnaires such the BASDAI,<sup>17</sup> HADS<sup>18</sup> or the Pittsburgh Sleep Quality Index.<sup>19</sup>

Finally, the referral checklist (Fig. 4) describes the criteria which should be considered for referring a patient who has certain comorbidities to other healthcare professionals, such as nurses, other medical specialists and other professionals such as occupational therapists or psychologists.

### Feasibility study

A total of eight healthcare professionals from seven different centres participated in this study, in which the checklists were used on 120 patients. Table 1 shows the main characteristics of the professionals and the participant centres. Seventy five per cent were women, with a mean age of  $48 \pm 6.4$  years, from high care level hospitals, with a number of rheumatologists per service which varied from 3 to 12 and a mean waiting time of 20 days to two months. Seventy five per cent of these centres had a monographic RA practice and half (four centres) a practice for AxSpA and PsA.

Regarding the feasibility study results (Table 2), a mean time of completion was estimated at  $7.88 \pm 3.55$  min,  $9.75 \pm 6.91$  min and  $4.75 \pm 4.15$  min for the comorbidity assessment checklists, comorbidity prevention and health promotion and referral, respectively.

The simplicity of the three checklists was high (Table 2), with means scores of 0 (nothing) to 10 (very/a lot) of  $8.86 \pm 1.36$  (assessment of comorbidity),  $7.86 \pm 2.23$  (comorbidity prevention and health promotion) and  $9.00 \pm .93$  (referral), as well as scores on user friendliness, clarity and usefulness (Table 2).

Furthermore, 100% of participants considered that the checklist of assessment of comorbidity would improve the daily practice and they would recommend it to their colleagues (Table 2). Equally, 63%

said that the checklists on comorbidity prevention and health promotion and referral would have a positive impact on daily practice (to determine new comorbidities, having a more overall view of the same) and 88% would recommend it to their colleagues.

## Discussion

The high prevalence and impact of comorbidity in RA, AxSpA and PsA is widely contrasted.<sup>1,10,12,13,20</sup>

In fact, different consensus and clinical practice guidelines', both national and international, recommend the systematic assessment and management of it in patients with this group of

## CUESTIONARIO

### COMORBILIDAD PACIENTE

Estimado paciente, a continuación le vamos a realizar una serie de preguntas sobre su salud. Y, en concreto, sobre las enfermedades que tenga o haya tenido.

El objetivo de este sencillo cuestionario es el de ayudar a los profesionales de la medicina y enfermería en la evaluación de su salud. Por ello, rellenar este cuestionario va a ser muy útil para que podamos planificar JUNTOS el tratamiento y el plan a seguir.

Queremos agradecerle enormemente de antemano su colaboración.

Y si tiene cualquier duda este cuestionario no dude en preguntarle a \_\_\_\_\_



#### 1. Señale el nombre de la enfermedad por la que viene a la consulta del reumatólogo

- |   |   |
|---|---|
| <input type="radio"/> Artritis reumatoide       | <input type="radio"/> Artritis psoriásica   |
| <input type="radio"/> Espondilitis anquilosante | <input type="radio"/> No sabe con precisión |

#### 2. Señale si ha tenido, tiene o toma medicación para alguno de los siguientes:

- |  |                                       |
|--|---------------------------------------|
| <input type="radio"/> Derrame/ trombosis cerebral/ictus                          |                                       |
| <input type="radio"/> Diabetes (azúcar en la sangre elevado)                     |                                       |
| <input type="radio"/> Sangrado digestivo/ úlcera sangrante en los últimos 5 años |                                       |
| <input type="radio"/> Bronquitis crónica/ EPOC                                   |                                       |
| <input type="radio"/> Ataque al corazón (infarto)                                | <input type="radio"/> Angina de pecho |
| <input type="radio"/> Arritmia   | <input type="radio"/> Trombosis       |
| <input type="radio"/> Tensión arterial alta                                      | <input type="radio"/> Colesterol alto |

#### 3. ¿Cuántos minutos de ejercicio hace al día?


Incluyendo en ejercicio, toda actividad física, también los desplazamientos a pie.

\_\_\_\_\_ minutos

#### 4. Indique el número de las siguientes bebidas que consume a la semana

Vino (copa) \_\_\_\_\_ Cerveza (caña) \_\_\_\_\_ Licores o copas \_\_\_\_\_

**Fig. 1.** Specific questionnaire for patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.

- 
5. ¿Es usted fumador?
- Sí ¿Cuántos cigarrillos fuma al día? \_\_\_\_\_  NO
6. Indique del 1 al 5 su estado de ánimo, siendo 1 muy bajo y 5 muy bueno.
- 1  2  3  4  5
7. ¿Tiene o ha tenido cáncer?
- Sí Tipo/s \_\_\_\_\_  NO
8. ¿Ha tomado usted antibióticos en el último año?
- Sí ¿Cuántas veces? \_\_\_\_\_ ¿Para qué? \_\_\_\_\_  
 NO
9. ¿Ha sido usted hospitalizado en el último año?
- Sí ¿Cuántas veces? \_\_\_\_\_ ¿Por qué motivo? \_\_\_\_\_  
 NO
10. ¿Ha acudido usted al servicio de urgencias en el último año?
- Sí ¿Cuántas veces? \_\_\_\_\_ ¿Por qué motivo? \_\_\_\_\_  
 NO
11. ¿Ha recibido alguna de las siguientes vacunas durante el último año?
- Gripe  Neumococo (para neumonía)  
 Hepatitis  Ninguna  
 Otra. Si lo recuerda, por favor, especifique cuáles \_\_\_\_\_
12. ¿Tiene usted algún problema ocular?
- NO  Ojo seco  Uveítis  
 Otros. Por favor especifique \_\_\_\_\_
13. ¿Ha tenido alguna vez una fractura?
- Sí ¿Cuándo? \_\_\_\_\_ ¿Toma algún tratamiento por este motivo? \_\_\_\_  
 NO

Muchísimas gracias por su colaboración.

Fig. 1. (Continued)

**Table 1**  
 Characteristics of the participants of the feasibility study.\*.

Variable	N (%)
Sex (women)	6 (75)
Age <sup>†</sup> (years)	48 ± 6.38
Regional/intermediate Hospital	1 (12)
General area/high level Hospital	7 (88)
Residents (yes)	5 (63)
Monographic RA practice	6 (75)
Monographic EspA practice	4 (50)
Monographic PsA practice	4 (50)

EspA: axial spondyloarthritis; PsA: psoriatic arthritis; RA: rheumatoid arthritis.

\* Results are expressed as numbers and percentages (%) unless otherwise indicated.

<sup>†</sup> Mean ± standard deviation.

diseases.<sup>21–25</sup> However, published data indicates that this assessment is sub-optimum.<sup>26,27</sup>

As a result, in recent years many projects have been developed to revert this situation. Specifically, the projects GECOAR,<sup>14</sup> GECOAX<sup>15</sup> and GECOPSA,<sup>16</sup> which were developed in Spain, and which generated a specific framework for the correct attention to comorbidity, for RA, AxSpA and PsA, in order to improve the previously described situation. Thus, data began to be published which suggested that all of these initiatives would have a positive impact

on daily practice, although we still had to continue improving to achieve appropriate comorbidity assessment and management.<sup>28</sup>

There is no doubt that the current high pressured healthcare of many centres in Spain may be clearly limited to the assessment of comorbidity following the framework described for each disease.<sup>14–16</sup> It is for this reason that the aim of the GECOAL project was to provide continuity to the approach of comorbidity and generate practical materials in the form of simple checklists of common use for this group of diseases.

For this proposal, we used what had been created from previous projects and also had help from published evidence, patient opinion and the knowledge and experience of a broad multidisciplinary group of experts. The checklists were also then assessed by a patient association and an association of healthcare professionals in rheumatology and the viability of three of them was analysed, reinforcing the validity of their contents.

We highlight as a new contribution to this project, the generation of a specific checklist for patients. This, as we have said, is based on their opinions. For its design we took into account their level of comprehension of medical language, relating to comorbidities, and their knowledge of them. Based on these factors, variables were arranged to be included in the checklist, to obtain the greatest quantity of information possible in a reliable format. An explanatory text suggested and argued by them was also included. The experts were convinced that this checklist will be of enormous help in subse-



## CHECKLIST

## COMORBILIDADES

## ALERGIAS

## MEDICACIÓN ACTUAL

## COMENTARIOS

## Cardiovascular

Peso \_\_\_\_\_  
 Talla \_\_\_\_\_  
 IMC \_\_\_\_/\_\_\_\_  
 Perímetro abdominal \_\_\_\_  
 TA \_\_\_\_/\_\_\_\_ mm Hg  
 Glucemia\* \_\_\_\_\_ mg/dl  
 Filtrado glomerular\* \_\_\_\_\_ ml/min

## Tabaco

- Sí (\_\_\_\_ cig/día, tiempo: \_\_\_\_\_)  
 Ex-fumador (tiempo: \_\_\_\_\_)  
 Nunca

## Ejercicio físico aeróbico (≥ 3 horas/semana)

- Sí  No

## Alcohol

- Sí (\_\_\_\_ ube/sem)  
 No

## Diabetes

- Sí (HbA1c= \_\_\_\_\_)  
 No

## Colesterol\*

- Total \_\_\_\_ mg/dl  
 HDL \_\_\_\_ mg/dl  
 LDLI \_\_\_\_ mg/dl  
 Triglicéridos \_\_\_\_ mg/dl

## Evento CV previo

- Sí \_\_\_\_\_  
 No

## Cáncer

Sí

Tipo: \_\_\_\_\_  
 Fecha diagnóstico: \_\_/\_\_/\_\_\_\_

Tipo: \_\_\_\_\_  
 Fecha diagnóstico: \_\_/\_\_/\_\_\_\_

Tipo: \_\_\_\_\_  
 Fecha diagnóstico: \_\_/\_\_/\_\_\_\_

Resolución/recaídas \_\_\_\_\_

No

## Depresión actual o ansiedad

- Sí  
 No

## Infecciones

- Sí  
 Graves: \_\_\_\_\_  
 De repetición (tipo): \_\_\_\_\_  
 Graves: \_\_\_\_\_  
 De repetición (tipo): \_\_\_\_\_  
 No

## Vacunas

- Gripe  
 Neumococo  
 Hepatitis  
 Otras: \_\_\_\_\_

## Serologías hepáticas

- VHB \_\_\_\_\_  
 VHC \_\_\_\_\_

## Otras complicaciones relacionadas con la enfermedad

- Uveítis  
 Sd Sjögren  
 Fractura/Osteoporosis  
 EII  
 Alteraciones sexuales  
 Alteraciones sueño  
 Disnea/EPID  
 Arritmias/bloqueos

## Otras

\_\_\_\_\_  
 \_\_\_\_\_

## Indicaciones:

- Todos los elementos se recogen en cada vista salvo que se indique \* que significa cadencia anual
- La presencia y tipo de cáncer se puede recoger solo una vez
- Se recogen infecciones que hayan precisado antibiótico/s. Es infección grave como aquella que precisa hospitalización.
- Las vacunas se recogerán al inicio de tratamientos y según los calendarios vacunales habituales

Fig. 2. Checklist of assessment of comorbidities for healthcare professionals.



## CHECKLIST

## PREVENCIÓN/PROMOCIÓN DE LA SALUD

A continuación enumeramos una serie de comorbilidades prevenibles (y su forma de evaluarlas/medirlas) con el fin de comprobar que se han realizado todos los procedimientos oportunos en relación a la prevención y promoción de la salud de los pacientes.



- o **Riesgo de fractura/Insuf. Vit D**  
Edad  
Peso  
Tabaco  
Alcohol  
AF y AP de fractura y localización  
Caña de bambú  
Niveles séricos vitamina D
- o **Riesgo cardiovascular**  
SCORE si el paciente no ha presentado ningún evento cardiovascular
- o **Obesidad/sobrepeso**  
IMC
- o **Sedentarismo**  
Preguntar
- o **Hepatopatía**  
Bioquímica hepática
- o **Gastropatía**  
Preguntar
- o **Adherencia al tratamiento**  
Preguntar o cuestionario específico
- o **Infecciones**  
Preguntar
- o **Higiene bucal**  
Preguntar
- o **Hábitos tóxicos**  
Preguntar o cuestionario específico
- o **Dieta saludable**  
Preguntar o cuestionario específico
- o **Estrés, depresión**  
Preguntar, HADS
- o **Trastorno del sueño**  
Item 6 de Pittsburgh Sleep Quality Index
- o **Fatiga**  
Item 1 del BASDAI / (MFSI-SF)
- o **Vida sexual**  
Preguntar o cuestionario específico
- o **Vida social**  
Preguntar o cuestionario específico

**Fig. 3.** Checklist on comorbidity prevention and health promotion in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.

quent assessment of comorbidity by healthcare professionals who attend patients.

We also wished to assess the comorbidity prevention and health promotion checklist. This was also highly novel, and we took into account its high impact for the patient<sup>10–13</sup> and the healthcare system,<sup>29–31</sup> critical to daily practice. For this reason the experts wish to reinforce this point with the highest development of similar initiatives, to help prevent maximum development of comorbidities.

In relation to the assessment checklists of comorbidity and referral, we would highlight their cross-sectional value, i.e. they are checklists which may be used indistinctly in the three before-mentioned diseases. Specifically, the assessment one contains the most relevant comorbidities (according to their prevalence and impact), although space is also available to record other different ones. Also, depending on the variables, other descriptive data are

collected which may be important for daily practice, accompanied by a series of easy-to-follow instructions. We would also highlight that the referral checklist is based, among other things, on criteria aged in a document by the Spanish Society of Rheumatology on referral in rheumatology.<sup>32</sup>

At the same time, another of the project novelties, which also provides great value to clinical practice, is the viability study of the healthcare professional checklists. The checklists were used in daily practice and assessed in relation to completion time; simplicity; clarity and usefulness. In general overall evaluation was highly positive. Completion time was not excessive and the majority of professionals considered that it would have a positive impact on their daily practice (for example for determining new comorbidities, having a global vision of them or preventing them better). Curiously, the general scores for the comorbidity assessment checklist were more positive compared with the other two. This may be

## CHECKLIST

## CRITERIOS DE DERIVACIÓN

A continuación describimos los especialistas y sus correspondientes criterios de derivación desde reumatología con el fin de comprobar que se han valorado.

Dependerá de su hospital.



## Enfermería

- Al inicio de tratamiento subcutáneo
- Al inicio de tratamiento con terapias biológicas
- Cuando el paciente por su patología (ej. cronicidad), tratamiento (ej. monitorización frecuente) y/o factores de riesgo (ej. obesidad, tabaquismo) precise una mayor formación y educación para su auto-cuidado.

## Terapia ocupacional

- Alteraciones articulares/musculares susceptibles de mejorar a través de productos de apoyo, ortesis
- Necesidad de llevar a cabo modificaciones en el entorno y adaptaciones funcionales del mismo
- Discapacidad superior a la esperada en el momento evolutivo de la enfermedad — Dificultad para la realización de las actividades de la vida
- Dependencia de aparición brusca o superior a la justificable por el estadio evolutivo de la enfermedad

## Psicología

- Cuando la respuesta al diagnóstico, a la enfermedad, al tratamiento y/o las consecuencias psicofísicas derivadas de los mismos, no es adaptativa
- Si hay ansiedad y/o depresión severas asociadas
- Si hay problemas sexuales asociados a la enfermedad
- Ante la sospecha de cualquier tipo de trastorno

## Gastroenterología

- Criterios mayores
- Rectorragia  
Diarrea crónica de características orgánicas  
Enfermedad perianal

- Criterios menores
- Dolor abdominal crónico  
Anemia ferropénica o ferropenia  
Déficit de vitamina B12  
Manifestaciones extraintestinales  
Fiebre o febrícula, sin focalidad  
Pérdida de peso no explicable  
Antecedentes familiares de EII

Se derivará al gastroenterólogo si se cumple UNO de los criterios mayores o AL MENOS DOS de los criterios menores

## Oftalmología

- Ojo rojo
- Pérdida de visión

## Cardiología

- Valvulopatía aórtica
- Sospecha de bloqueo aurículo-ventricular

## Nutricionista

- Mal control del peso

## Dermatología

## Neumología

## Nefrología

Fig. 4. Checklist of patient referral, to other healthcare professionals.

Table 2

Results from the feasibility study of healthcare professionals checklists.\*

	Checklists		
	Comorbidities assessment	Comorbidity prevention and health promotion	Referral
Time (minutes) used for completion	7.88 ± 3.55	9.75 ± 6.91	4.75 ± 4.15
Simplicity (0–10) <sup>†</sup>	8.86 ± 1.36	7.86 ± 2.23	9.00 ± .93
User-friendliness (0–10) <sup>†</sup>	8.57 ± 1.50	7.43 ± 1.76	7.86 ± 1.64
Clarity (0–10) <sup>†</sup>	9.29 ± 0.70	8.43 ± 1.40	9.43 ± .49
Usefulness (0–10) <sup>†</sup>	8.71 ± 1.39	8.14 ± 1.55	7.43 ± 1.68
Improvement in clinical practice (yes)	100%	63%	63%
Recommendation to colleagues (yes)	100%	88%	88%
Need for checklist revision (yes)	12%	37%	25%

Evaluation scales 0–10: 0: nothing; 10: very, a lot.

\* Results are expressed as numbers and percentages (%) unless otherwise indicated.

† Mean ± standard deviation.



due to the fact that we are still not very familiar with comorbidity prevention and health promotion. In the case of referral, this may be subject to other conditioning factors related to local environment. We have already highlighted the importance of comorbidity prevention and the promotion of health in our day to day practice, and we also consider that good coordination between professionals is essential for addressing comorbidities appropriately.

The GECOAI Project does, however, have a series of limitations. The first derives from the choice of variables included in the checklists. Notwithstanding, it is improbable that something relevant is missing, since it is taken from studies which have already assessed these aspects, and also the evaluation checklists are open to the inclusion of other variables from each consultation practice. Lack of familiarity with comorbidity prevention and health promotion could be a barrier to the initial implementation of the checklists. The main limitation, however, is that we have not yet demonstrated that their use has brought about improvements to the health of the patients. However, the experts believe it is probable that this will occur. This would be the aim of future projects. We should, however, point out several aspects on the use and limitations of this type of tool in our clinical practice (often with great healthcare pressure). Just as we have described, there is not one, but three checklists, which require time for completion and this could limit their implementation in daily practice. However, in the feasibility study, the mean time employed for use was reasonable and dropped as they were familiarized. This is precisely the aim and advantage of the checklists: that the clinician is able to naturally standardise and incorporate several control tools for optimising clinical management.

To sum up, with this project we have created four checklists for the management of comorbidity to be commonly used in patients with RA, AxSpA and PsA, and which are simple and viable regarding implementation in daily practice. We are convinced that with them we will help to improve both the health of the patients and their healthcare. However, it is important to determine their real use in a few years time through their real implementation in clinical practice.

## Financing

This Project was financed by Merck Sharp & Dohme® España and endorsed by the following associations/societies: CONARTITIS (National coordinator of the arthritis association of patients representing persons affected by RA, PsA, JIA and EspA), OPENREUMA (Association of other healthcare professionals dedicated to rheumatology) and SORCOM (Rheumatology Society of the Community of Madrid). Merck Sharp & Dohme® had no impact on project development or the final manuscript content.

## Conflict of interests

MG has collaborated as consultant or researcher with MSD®, Abbvie®, Sanofi® and Pfizer®. SC has received research grants or aids from MSD®, Pfizer® and Roche®. In recent years they have also received occasional fees for papers and/or consultations from Abbvie®, Amgen®, BMS®, Celgene®, Gebro-Pharma®, Janssen®, Lilly®, MSD®, Pfizer®, Roche®, Stada®, Theramex® and UCB®.

## Acknowledgements

The authors would like to thank Dr. Ana M. Ortiz, from the rheumatology unit of the University Hospital La Princesa, Madrid, for her comments and constructive criticisms of the checklists.

## References

- Carmona L, Villaverde V, Hernandez-García C, Ballina J, Gabriel R, Laffon A, et al. The prevalence of rheumatoid arthritis in the general population of Spain. *Rheumatology* (Oxford). 2002;41:88–95.
- López-Medina C, Moltó A. Update on the epidemiology, risk factors, and disease outcomes of axial spondyloarthritis. *Best Pract Res Clin Rheumatol*. 2018;32:241–53.
- López Estebarán JL, Zarco-Montejo P, Samaniego ML, García-Calvo C, PREVAL-Study Group. Prevalence and clinical features of psoriatic arthritis in psoriasis patients in Spain. Limitations of PASE as a screening tool. *Eur J Dermatol*. 2015;25:57–63.
- Carmona L, González-Alvaro I, Balsa A, Angel Belmonte M, Tena X, Sanmartí R. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. *Ann Rheum Dis*. 2003;62:897–900.
- Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). *Ann Rheum Dis*. 2014;73:62–8.
- Molto A, Etcheto A, van der Heijde D, Landewé R, van den Bosch F, Bautista Molano W, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. *Ann Rheum Dis*. 2015;75:1016–23.
- Castañeda S, Martín-Martínez MA, González-Juanatey C, Llorca J, García-Yébenes MJ, Pérez-Vicente S, et al. Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: baseline data of the CARMA Project. *Semin Arthritis Rheum*. 2015;44:618–26.
- Radner H, Lesperance T, Accortt NA, Solomon DH. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. *Arthritis Care Res* (Hoboken). 2017;69:1510–8.
- Özkan SG, Yazisiz H, Behlül A, Gökbelen YA, Borlu F, Yazisiz V. Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with psoriatic arthritis. *Eur J Rheumatol*. 2017;4:40–5.
- Radner H, Ramiro S, Buchbinder R, Landewé RB, van der Heijde D, Aletaha D. Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity. *Cochrane Database Syst Rev*. 2012;1:CD008951.
- An J, Nyarko E, Hamad MA. Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis. *Clin Rheumatol*. 2019;38:2717–26.
- Radner H, Smolen JS, Aletaha D. Impact of comorbidity on physical function in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2010;69:536–41.
- Fernández-Carballido C, Martín-Martínez MA, García-Gómez C, Castañeda S, González-Juanatey C, Sánchez-Alonso F, et al. Impact of comorbidity on physical function in patients with ankylosing spondylitis and psoriatic arthritis attending rheumatology clinics: results from a cross-sectional study. *Arthritis Care Res* (Hoboken). 2019;72:822–8.
- Loza E, Lajas C, Andreu JL, Balsa A, González-Álvoro I, Illera O, et al. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. *Rheumatol Int*. 2015;35:445–58.
- González C, Curbelo Rodríguez R, Torre-Alonso JC, Collantes E, Castañeda S, Hernández M, et al. Recomendaciones para el manejo de la comorbilidad en la práctica clínica en pacientes con Espondiloartritis Axial. *Reumatol Clin*. 2017;14:346–59.
- Torre-Alonso JC, Carmona L, Moreno M, Galíndez E, Babío J, Zarco P, et al. Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. *Rheumatol Int*. 2017;37:1239–48.
- Cardiel MH, Londoño JD, Gutiérrez E, Pacheco-Tena C, Vázquez-Mellado J, Burgos-Vargas R. Translation, cross-cultural adaptation, and validation of the Bath Ankylosing Spondylitis Functional Index (BASFI), the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Dougados Functional Index (DFI) in a Spanish speaking population with spondyloarthropathies. *Clin Exp Rheumatol*. 2003;21:451–8.
- Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. A validation study of the hospital anxiety and depression scale (HADS) in a Spanish population. *Gen Hosp Psychiatry*. 2003;25:277–83.
- Hita-Conterras F, Martínez-López E, Latorre-Román PA, Garrido F, Santos MA, Martínez-Amat A. Reliability and validity of the Spanish version of the Pittsburgh Sleep Quality Index (PSQI) in patients with fibromyalgia. *Rheumatol Int*. 2014;34:929–36.
- U.S. Preventive Services Task Force. Screening for impaired visual acuity in older adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2009;151:37–43.
- Wending D, Lukas C, Prati C, Claudepierre P, Gossec L, Goupille P, et al. 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. *Joint Bone Spine*. 2018;85:275–84.
- van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Ann Rheum Dis*. 2017;76:978–91.
- Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of

- ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis Rheumatol.* 2016;68:282–98.
24. Roubille C, Richer V, Starnino T, McCourt C, McFarlane A, Fleming P, et al. Evidence-based recommendations for the management of comorbidities in rheumatoid arthritis, psoriasis, and psoriatic arthritis: expert opinion of the canadian dermatology-rheumatology comorbidity initiative. *J Rheumatol.* 2015;42:1767–80.
  25. Sociedad Española de Reumatología. Available from Guía de Práctica Clínica para el Tratamiento de la Espondiloartritis Axial y la Artritis Psoriásica; 2015 <https://www.ser.es/espoguia/>
  26. Maese J, García De Yébenes MJ, Carmona L, Hernández-García C, Grupo de Estudio emAR II. Management of rheumatoid arthritis in Spain (emAR II). Clinical characteristics of the patients. *Reumatol Clin.* 2012;8:236–42.
  27. Casals-Sánchez JL, García De Yébenes Prous MJ, Descalzo Gallego MA, Barrio Olmos JM, Carmona Ortells L, Hernández-García C, et al. Characteristics of patients with spondyloarthritis followed in rheumatology units in Spain. emAR II study. *Reumatol Clin.* 2012;8:107–13.
  28. Almodovar R, Joven B, Rodríguez Almaraz E, Melchor S, Rabadán E, Villaverde V, et al. Implementation of an assessment checklist for patients with spondyloarthritis in daily practice. *Clin Exp Rheumatol.* 2020;38:115–21.
  29. Li N, Chan E, Peterson S. The economic burden of depression among adults with rheumatoid arthritis in the United States. *J Med Econ.* 2019;22:372–8.
  30. Merola JF, Herrera V, Palmer JB. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. *Clin Rheumatol.* 2018;37:2751–61.
  31. Lee JS, Oh BL, Lee HY, Song YW, Lee EY. Comorbidity, disability, and healthcare expenditure of ankylosing spondylitis in Korea: a population-based study. *PLoS One.* 2018;13:e0192524.
  32. Gobbo M, Marco E, López Medina S, Ortega García P, Zubizarreta C, Inhiesta I, et al. Criterios de derivación de reumatología a Rehabilitación y Fisioterapia. *Reumatol Clin.* 2013;9(Espec Cong 1):1.